Hexatherapy treatment improved tumor growth control in primary and metastatic 4T1 settings compared with all the combinations tested (figure 4B–D) by promoting effector CD4+ and CD8+ cells while at the same time limiting T cell exhaustion. The gene discussed is CD4; the disease is neoplasm.